Medicus Pharma Ltd
MDCX2.300USD
+0.100+4.55%
Fechamento 11/05, 16:00（ET）Cotações atrasadas em 15 min
36.65MValor de mercado
PerdaP/L TTM
Mais detalhes de Medicus Pharma Ltd Empresa
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
Informações de Medicus Pharma Ltd
Código da empresaMDCX
Nome da EmpresaMedicus Pharma Ltd
Data de listagemOct 11, 2023
CEODr. Raza Bokhari, M.D.
Número de funcionários12
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 11
Endereço100 King Street West
CidadeTORONTO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísCanada
Código postalM5X 1A4
Telefone17323003046
Sitehttps://medicuspharma.com/
Código da empresaMDCX
Data de listagemOct 11, 2023
CEODr. Raza Bokhari, M.D.
Executivos da empresa Medicus Pharma Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F Bonner
Ms. Carolyn F Bonner
President, Acting Chief Financial Officer
President, Acting Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Edward J. Brennan, Jr., M.D.
Dr. Edward J. Brennan, Jr., M.D.
Chief Scientific Officer, Head of Research and Development Program
Chief Scientific Officer, Head of Research and Development Program
--
--
Mr. Frank W. Lavelle
Mr. Frank W. Lavelle
Independent Director
Independent Director
--
--
Dr. Sara R. May, Ph.D.
Dr. Sara R. May, Ph.D.
Director
Director
--
--
Mr. Barry Fishman, CPA
Mr. Barry Fishman, CPA
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F Bonner
Ms. Carolyn F Bonner
President, Acting Chief Financial Officer
President, Acting Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 30 de out
Atualizado em: qui, 30 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Velocity Fund Partners LP
13.23%
215 Capital Togo PHL Fund I, LP
9.32%
Interchange Capital Partners LLC
7.40%
Hathaway (John)
3.73%
Bokhari (Raza)
3.70%
Outro
62.62%
Investidores
Investidores
Proporção
Velocity Fund Partners LP
13.23%
215 Capital Togo PHL Fund I, LP
9.32%
Interchange Capital Partners LLC
7.40%
Hathaway (John)
3.73%
Bokhari (Raza)
3.70%
Outro
62.62%
Tipos de investidores
Investidores
Proporção
Corporation
22.55%
Individual Investor
11.46%
Investment Advisor
9.06%
Hedge Fund
0.44%
Bank and Trust
0.12%
Research Firm
0.07%
Investment Advisor/Hedge Fund
0.02%
Outro
56.28%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
28
2.08M
9.71%
-1.07M
2025Q2
22
10.21M
64.09%
+108.37K
2025Q1
19
10.07M
84.39%
+1.61M
2024Q4
12
8.43M
77.76%
+1.48M
2024Q3
8
6.05M
68.59%
+2.33M
2024Q2
7
4.05M
50.15%
+329.10K
2024Q1
9
3.82M
47.35%
+3.82M
2023Q4
9
3.82M
47.35%
+3.82M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Velocity Fund Partners LP
2.84M
14.04%
--
--
Jun 30, 2025
215 Capital Togo PHL Fund I, LP
2.00M
9.89%
--
--
Sep 22, 2025
Interchange Capital Partners LLC
1.59M
7.85%
-75.00K
-4.51%
Jun 30, 2025
Hathaway (John)
800.95K
3.96%
--
--
Jun 30, 2025
Bokhari (Raza)
793.17K
3.92%
--
--
Sep 22, 2025
Melani (Kenneth)
409.41K
2.02%
--
--
Jun 30, 2025
Quinlan (James P)
274.15K
1.36%
--
--
Sep 22, 2025
Private Advisor Group LLC
146.00K
0.72%
+89.25K
+157.27%
Jun 30, 2025
Brennan (Edward Joseph JR)
86.50K
0.43%
--
--
Sep 22, 2025
Verition Fund Management LLC
53.38K
0.26%
+53.38K
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
